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Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common type of primary liver cancer. Only
few studies have focused on palliative radiotherapy used for patients who weren’t suitable for resection by surgery.
This study was conducted to investigate the effect of external beam radiotherapy (EBRT) for patients with
unresectable ICC.
Methods: We identified 84 patients with ICC from December 1998 through December 2008 for retrospective
analysis. Thirty-five of 84 patients received EBRT therapy five times a week (median dose, 50 Gy; dose range, 30-60 Gy,
in fractions of 1.8-2.0 Gy daily; EBRT group); the remaining 49 patients comprised the non-EBRT group. Tumor
response, jaundice relief, and survival rates were compared by Kaplan-Meier analysis. Patient records were reviewed
and compared using Cox proportional hazard analysis to determine factors that affect survival time in ICC.
Results: After EBRT, complete response (CR) and partial response (PR) of primary tumors were observed in 8.6%
and 28.5% of patients, respectively, and CR and PR of lymph node metastases were observed in 20% and 40% of
patients. In 19 patients with jaundice, complete and partial relief was observed in 36.8% and 31.6% of patients,
respectively. Median survival times were 5.1 months for the non-EBRT group and 9.5 months for the EBRT group
(P = 0.003). One-and two-year survival rates for EBRT versus non-EBRT group were 38.5% versus 16.4%, and 9.6%
versus 4.9%, respectively. Multivariate analysis revealed that clinical symptoms, larger tumor size, no EBRT, multiple
nodules and synchronous lymph node metastases were associated with poorer prognosis.
Conclusions: EBRT as palliative care appears to improve prognosis and relieve the symptom of jaundice in patients
with unresectable ICC.
Background
Intrahepatic cholangiocarcinoma (ICC) is the second
most common type of primary liver cancer. A recent
study from the United States reported a 9% annual
increase and an overall tenfold increase in ICC-related
mortality since 1973 [1].
Lack of symptoms until late in the disease typically
results in advanced ICC at the time of diagnosis, and
cure rates are low for patients with advanced stage dis-
ease, even with aggressive therapy. Overall resectability
rates were 54.6% in a series from Japan [2] and 62% in a
series from United States [3]; 1-and 3-year cumulative
survival rates in the resected cases were 49.4% to 76.6%
and 17.3% to 52.7%, respectively [4-7]. Among the unre-
sectable cases, median survival was less than 5 months
[8-10], which represents a rapidly fatal process.
Surgical resection is the only potentially curative treat-
ment; however, disease is already unresectable at presen-
tation in some patients. Most of these patients are
candidates for palliative therapy, which includes biliary
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moembolization (TACE), and photodynamic therapy.
However, cholangiocarcinomas respond poorly to exist-
ing therapies, so these palliative options are of limited
benefit [11].
Although a few studies have focused on palliative
radiotherapy for these patients, no controlled trials have
been conducted. The purpose of the current study was
to evaluate the clinical effectiveness of radiotherapy in
patients with unresectable ICC by retrospective analysis
and to identify prognostic factors associated with clinical
outcomes.
Methods
During the period from December 1998 to December
2008, a total of 549 patients with ICC were hospitalized
in the Liver Cancer Institute, Zhongshan Hospital,
Fudan University, among which 406 patients underwent
hepatectomy, and the remaining 143 were unresectable.
Unresectable ICC was determined by surgeons and the
following clinical conditions were considered to be
unresectable: extensive bilobular involvement of the
liver by a large solitary tumor or by multiple tumors, or
invasion of major blood vessels. Of 143 unresectable
patients, 59 were excluded from this study, among
which 14 patients had Child-Pugh C or other serious
diseases, and 45 patients were diagnosed by clinic pre-
sentation. The remaining 84 patients were confirmed by
histological examination combined with medical history
a n de x c l u d e df r o mH C Ca n dm e t a s t a s e sf r o mg a s t r o i n -
testinal cancers by immunohistochemical staining of
CK7, CK19, CK20, AFP, MUC5AC, MUC6 and Hepa
(Table 1). Abdominal and pelvic examination by CT/
MRI scan or endoscopy was also performed to confirm
no evidence of gastrointestinal cancers; tumor markers
such as carcinoembryonic antigen (CEA), carbohydrate
antigen 19-9 (CA19-9), and alphafetoprotein (AFP) were
also used to differentiate ICC from other liver tumors.
Among 84 patients included in this study, 35 patients
receiving external beam radiotherapy (EBRT; EBRT
group) and 49 patients did not receive radiotherapy (con-
trol non-EBRT group). In EBRT group, one patient (2.9%)
belonged to TNM-I stage, followed by 8 to TNM-II stage
(22.9%), 9 to TNM-III stage (25.7%), 12 to TNM-IVa stage
(34.3%), and 5 to TNM-IVb stage (14.3%), according to
the 7th edition of UICC-TNM staging system for ICC
[12]; In non-EBRT group, six patients (12.2%) belonged to
TNM-II stage, followed by 10 to TNM-III stage (20.4%),
and 29 to TNM-IVa (59.2%), and 4 to TNM-IVb stage
(8.2%). Transarterial chemoembolization (TACE) was also
used in 28 patients, including 15 patients from EBRT
group and 13 from non-EBRT group. We identified these
patients to determine the role of TACE in the treatment
of unresectable ICC. Because the role of chemotherapy is
undefined in ICC, no systemic chemotherapy was admi-
nistered during the entire treatment period. This study
was approved by the ethical review board of Zhongshan
Hospital, Fudan University and in compliance with the
Helsinki Declaration of 1975, as revised in 2000.
ICC is defined as a tumor arising peripheral to the
secondary bifurcation of the left or right hepatic duct.
Thus, tumors arising from the right and/or left hepatic
ducts were excluded from the study. However, there
were significant differences between the clincopathologi-
cal features of ICC and outcome in patients with tumors
located close to the hilarum peripherally [13]; accord-
ingly, ICC was topographically divided into two types: a
central type, in which the carcinoma was related to a
major intrahepatic bile duct, and a peripheral type. Syn-
chronous lymph node (LN) metastasis was defined as a
diagnostic interval between ICC and extrahepatic LN
metastasis of not longer than 1 month. Patient demo-
graphics and baseline characteristics are displayed in
Table 2.
Therapies
Each patient provided written informed consent regard-
ing the treatment course. Patients received limited-field
EBRT using a linear accelerator with 6-or 15-MV
photons. Prior to June 2005, traditional (two-dimen-
sional) design and delivery of EBRT relied on a CT/MRI
scan of the abdomen to show the position of the tumor
using a simulation process (n = 13) [14]. Since July
2005, three-dimensional conformal radiation therapy
was used (n = 22). For EBRT planning, the patients
underwent CT in the supine position with both arms
raised above the head; CT images were then transferred
to a three-dimensional conformal radiation therapy
Table 1 Immunochemical analysis of liver tumors
Hepa CK7 CK19 CK20 AFP MUC5AC MUC6
Hepatocellular carcinoma + - - - +/- - -
Hepatic metastasis
from gastric cancer
- + + - - +/- -
Hepatic metastasis
from colorectal cancer
- -/+ - + - - +
Intrahepatic cholangiocarcinoma - + + - - + -
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Page 2 of 9planning system (Pinnacle 7.6C). Gross tumor volume
(GTV) included the primary tumor and involved lymph
nodes. Clinic target volume (CTV) was defined as GTV
with a 5-mm margin, and included regional nodes areas
for LN involvement. Planning target volume (PTV) was
defined as clinical target volume with a 5-to 7-mm mar-
gin to account for daily setup error, with cephalic and
caudal margin enlargement (1-1.5 cm) for respiratory
motion. Figure 1 represents a typical case demonstrating
targeting volume.
We scheduled the full radiation dosage up to 50 to
60 Gy. For patients with synchronous LN metastasis,
typical EBRT practice in our department was to deliver
40 Gy to the PTV with 10 to 20 Gy delivered to the
GTV as boost fields. A reduced dose was considered
after evaluating adverse effects, liver function, and
distant metastases during EBRT, and an increased dose
was delivered if patients tolerated therapy well (five
times a week; dose range, 30-60 Gy; daily fraction,
1.8-2.0 Gy; Table 3). If all or part of the right kidney
was in the radiation field, an initial left renal evaluation
with intravenous pyelography was performed to ensure
adequate function of the left kidney. When the duode-
num was encompassed within the EBRT fields, the total
EBRT dose was limited to ≤ 54 Gy.
TACE is a combination of targeting chemotherapy
with 5-fluorouracil (1 g), cisplatin (80 mg), mitomycin
C (10 mg), and arterial embolization with10 mL iodized
oil (Lipiodol Ultra Fluid; Laboratory André Guerbet,
Aulnay-sous-Bois, France) mixed with 10 mg mitomycin
C, which produces both a selective ischemic effect and a
chemotherapeutic effect on primary liver cancer.
Follow-up, assessment of response, and toxicity
Pretreatment evaluation included a medical history and
physical examination; complete blood cell count; liver
function test; AFP, CEA, or CA 19-9 (Roche Diagnostics,
Indianapolis, IN); abdominal ultrasonography; and
enhanced CT or MRI. Clinical monitoring was performed
weekly. Patients were advised to return for an initial
follow-up examination 6 weeks after EBRT completion,
during which irradiation responses were evaluated by
abdominal enhanced CT scan or MRI. Patients were
monitored every 3 months thereafter. Complete response
(CR) was defined as complete tumor disappearance based
on radiographic evidence; partial response (PR) required
a ≥ 50% reduction in the sum of the products of the
tumor’s longest diameter and its perpendicular by CT or
MRI. Stable disease (SD) indicated a < 50% decrease or a
< 25% increase in the product of the longest perpendicu-
lar diameters of measurable tumors. Progressive disease
(PD) was defined as an increase of ≥ 25% in the sum of
the products of the tumor’s longest diameter and its per-
pendicular, compared with the lowest value recorded, or
as death from ICC within 3 months. Objective response
was calculated for CR and PR; no response was calculated
for SD or PD.
Twenty-five patients in the EBRT-group exhibited
jaundice before treatment. Complete jaundice relief was
defined as disappearance of symptoms and total biliru-
bin at normal level (≤17.1 μmol/L), partial jaundice
relief was defined as disappearance of symptoms but
total bilirubin higher than normal ( > 17.1 μmol/L), but
more than two-fold lower than the pre-radiation level.
Table 2 Patient demographics and baseline
characteristics
Non-EBRT
(n = 49)
EBRT
(n = 35)
P-value
Sex, n (%) 0.308
Male 32 (65.3%) 19 (54.3%)
Female 17 (34.7%) 16 (45.7%)
Age, n (%) 0.631
≤60 years old 25(51.0%) 16 (45.7%)
>60 years old 24(49.0%) 19 (64.3%)
Clinical symptoms, n (%) 0.386
Asymptomatic 9(18.4%) 4 (11.4%)
Symptomatic 40(81.6%) 31 (88.6%)
Diameter, mean ± SE (cm) 8.6 ± 3.4 7.7 ±3.2 0.238
≤5, n (%) 6(12.2%) 7 (20.0%) 0.280
5-10, n (%) 21 (44.9%) 18 (51.4%)
≥10, n (%) 22 (44.9%) 10 (28.6%)
Intrahepatic lesions, n (%) 0.898
Solitary 37(75.5%) 26 (74.3%)
Multiple nodules 12 (24.5%) 9 (25.7%)
Tumor Types, n (%) 0.722
Peripheral ICC 34 (69.4%) 23 (65.7%)
Central ICC 15 (30.6%) 12 (34.3%)
Synchronous LN metastases, n (%) 0.064
No 18 (36.7%) 20 (57.1%)
Yes 31 (63.3%) 15 (42.9%)
CA19-9, U/mL 0.676
≤37, n (%) 9 (18.4%) 4 (11.4%)
37-600, n (%) 15 (30.6%) 11 (31.4%)
≥600, n (%) 25 (51.0%) 20 (57.1%)
TACE, n (%) 0.118
Yes 13(26.5%) 15(42.9%)
No 36(73.5%) 20(57.1%)
TNM stage, n (%) 0.175
I 1(2.9%)
II 6(12.2%) 8(22.9%)
III 10(20.4%), 9(25.7%)
IVA 29(59.2%) 12(34.3%)
IVB 4(8.2%) 5(14.3%)
EBRT, external beam radiotherapy; TACE, transcatheter arterial
chemoembolization; SE, standard error; ICC, intrahepatic cholangiocarcinoma;
LN, lymph node.
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jaundice before EBRT were first referred to ultrasono-
graphy for decompression via percutaneous transhepatic
catheter placement and then treated with EBRT. Jaun-
dice relieved without catheter placement after the
completion of EBRT was described as “jaundice was
relieved.”
The overall survival period was defined as the period
from the date of ICC diagnosis to the date of death or
the last follow-up appointment. Toxicity was evaluated
according to the Radiation Therapy Oncology Group
(RTOG) Toxicity Criteria, Version 2.0 [15]. Radiation-
induced liver disease(RILD)was defined as either a mini-
mum two-fold increase in anicteric elevation of ALP
and non-malignant ascites or a minimum five-fold
increase in elevated transaminases over the upper limit
of normal or of pretreatment levels (Grade 3 or 4 hepa-
tic toxicity by RTOG toxicity criteria) within 4 months
after completion of radiotherapy.
Statistical analysis
Survival analyses were carried out with the Kaplan-Meier
method. We considered the date of ICC diagnosis as
time zero, and patients alive at the end of follow-up were
considered censored. Chi-square (c
2) test was used to
compare the prevalence of ICC characteristics between
the two groups and to assess dose-response relationships.
Multivariate analysis of survival was carried out with
Figure 1 Three-dimensional conformal radiation therapy for intrahepatic cholangiocarcinoma (ICC) patient with asynchronous hepatic
portal, peri-pancreas, and para-aorta lymph node metastases, showing delineation of plan tumor target volume 1 (PTV1) and plan
target volume 2 (PTV2) for 50.4 Gy/28 Fx and 41.4 Gy/23 Fx, dose distribution, and dose volume histogram (DVH) for tumor targets
and organs at risk.
Table 3 External beam radiotherapy (EBRT) treatment
Radiotherapy characteristics n (%)
Radiation dose (Gy)
30-48 5 (14.3%)
50 21(60.0%)
52-60 9(25.7%)
Irradiation Site
Primary tumor only 20 (57.1%)
Primary tumor and LN metastases 15 (42.9%)
PTV volumes* (cm3)
Minimum. 58.76
Maximum. 1087.65
Mean ± SD 382.29 ± 323.92
LN, lymph node; PTV, planning target volume; SD, standard error.
*The data of PTV volumes were only gathered from the patients who received
three-dimensional conformal radiation therapy.
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a single step using backward stepwise regression (likeli-
hood ratio). P < 0.05 was considered significant. All
calculations were performed using SPSS version 15.0 for
Windows (Chicago, IL).
Results
Response to EBRT
Of the 35 patients with unresectable ICC who underwent
EBRT, primary tumors were irradiated in 35 patients:
three patients (8.6%) achieved a CR, and ten (28.5%)
achieved a PR at the first follow-up exam, resulting in an
objective response rate of 37.1%. SD was observed in 17
patients (48.6%), with an overall disease control rate of
85.7%. Of the 35 patients, 15 received TACE. Among
these 15 patients, one (6.7%) achieved CR and four
(26.7%) showed PR, with an overall objective response
rate of 33.3%. SD was observed in 8 patients (53.3%),
with an overall disease control rate of 86.7%.
LN metastases were irradiated in 15 patients: three
patients (20%) achieved a CR, and six (40%) achieved a
PR, resulting in an objective regression rate of 60%.
Of the 19 patients in the EBRT-group with jaundice
symptom before EBRT, jaundice was completely relieved
in seven patients (36.8%) and partially relieved in six
patients (31.6%) after EBRT completion. The total relief
rate was 68.4%.
Overall survival analysis and prognosis factors
At the time of analysis, 78 patients had died, 1 was lost
to follow-up, and 5 were still alive. The median survival
time for all patients was 6.8 ± 0.9 months.
In this study, 1-and 2-year survival rates for patients
with unresectable ICC treated with EBRT (n = 35) com-
pared with the non-EBRT group (n = 49) were 38.5%
versus 16.4%, and 9.6% versus 4.9%, respectively. Median
survival times were 9.5 ± 1.1months versus 5.1 ± 0.3
months, respectively (log-rank P = 0.003) (Figure 2).
One-and two-year survival rates for patients with
unresectable ICC treated with TACE (n = 28) compared
with those who did not undergo TACE (n = 56) were
39.9% versus 16.6%, and 4.0% versus 8.3%, respectively.
Median survival times were 10.0 ± 1.4 months versus
5.9 ± 0.7 months, respectively (log-rank P = 0.201).
Furthermore, In non-EBRT group, survival rates at 1
and 2 years were 18.5%/13.4%, and 0%/6.7% for treat-
ment with TACE (n = 13) and non-TACE (n = 36),
respectively; Median survival times were 5.4 ± 3.1
months versus 4.9 ± 0.3 months, respectively (log-rank
P = 0.867). In EBRT group, survival rates at 1 and 2
years were 57.8%/22.7%, and 7.2%/11.4% for treatment
with TACE (n = 15) and non-TACE (n = 20), respec-
tively; Median survival times were 13.3 ± 1.5 months
versus 7.8 ± 1.0 months, respectively (log-rank P = 0.268).
For the patients who did not undergo EBRT, median
survival times for peripheral ICC (n = 34) and central
ICC (n = 15) were 5.4 ± 0.7 months and 3.5 ± 1.1
months, respectively (P = 0.103). In contrast, median
survival times for peripheral ICC (n = 23) and central
ICC (n = 12) in the EBRT group were 8.5 ± 0.9 months
and 13.3 ± 3.6 months, respectively (P = 0.205), and the
tumor response rates were 26.1% (n =6 )a n d5 8 . 3 %
(n = 7), respectively (P = 0.061). In addition, the mean
tumor diameter in central ICC was significantly smaller
compared with that of peripheral ICC (9.0 ± 3.4 cm ver-
sus 6.7 ± 2.7 cm (P = 0.003) (Table 4).
The results of multivariate survival analysis are
displayed in Table 5. Five factors appear to be indepen-
dently associated with poorer prognosis: clinical symp-
toms, synchronous LN metastases, larger tumor size,
multiple nodules and no EBRT. However, TACE
was not an independent factor for unresectable ICC
(RR = 0.893, P = 0.689).
Failure pattern
Thirty-two of 35 patients in the EBRT group died; causes
of death included liver failure induced by tumor progres-
sion (n = 22, 68.8%), liver failure induced by radiation-
induced liver failure (n = 1, 3.1%), distant metastases
(lungs or brain) (n = 5, 15.6%), abdominal LN metastases
(n = 2, 6.3%), cancer cachexia (n = 2, 6.3%).
Forty-six of 49 patients in the non-EBRT group died;
causes of death included liver failure induced by intrahe-
patic tumor progression (n = 35, 76.1%), distant metas-
tases (lungs or brain) (n =4 ,8 . 7 % ) ,a b d o m i n a lL N
metastases (n = 5, 10.9%), cancer cachexia (n = 1, 2.2%),
and unknown cause (n = 1, 2.2%). There was no signifi-
cant difference in main cause of death between these
two groups (P = 0.344).
Adverse events
Table 6 lists adverse events during and after EBRT.
Adverse events from EBRT included increased liver
enzymes after the completion of EBRT, but most of
them were less than grade 2. Hematologic adverse
events were not severe; some may have been due to por-
tal hypertension and associated hypersplenism, and the
lower hemoglobin may have resulted from malnutrition.
Nine patients (9/13) had nausea/vomiting during the
last course of EBRT. One patient developed RILD and
eventually developed liver failure resulting in mortality.
Discussion
Results of the present study demonstrate that EBRT was
associated with improving survival in patients with unre-
sectable ICC. Patients with central ICC appear to benefit
more from radiation compared with patients with per-
ipheral ICC.
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gical approach is warranted in patients with peripheral
ICC because resection offers the only hope for long-
term survival [4-7,16]. Unfortunately, most patients pre-
sent with advanced disease because peripheral ICC is
usually asymptomatic in an earlier stage. Recently, the
majority of studies that showed benefits from therapy
used a combination of EBRT and intraluminal iridium
(Ir
192) for patients with extrahepatic cholangiocarcinoma
[17]. However, few reports have focused on intrahepatic
cholangiocarcinoma, and no controlled trials have evalu-
ated the combination of EBRT and intraluminal iridium
in that patient group. This is partially because transcath-
eter brachytherapy boosts are not feasible in the patients
with peripheral or intrahepatic hilar cholangiocarci-
noma; other reports show no survival benefit for EBRT
in ICC [18].
Experience with EBRT is growing, but few reports
provide data needed to compare treatment with and
without EBRT in patients with unresectable ICC. There-
fore, radiotherapy in unresectable ICC was evaluated in
this 10-year retrospective study. The findings of the pre-
sent study are useful not only for assessing patient prog-
nosis but also for evaluating the efficacy of palliative
treatments. EBRT can be administered for local tumor
control in an attempt to improve the survival time while
maintaining an acceptable quality of life.
Among patients received radiotherapy, median survival
time associated with central ICC was longer compared
with peripheral ICC (13.3 versus. 8.5 months). A possi-
ble reason is that central ICC is closer to the hilus hepa-
tis and is prone to obstructing the common bile duct,
causing jaundice and leading to an earlier diagnosis. In
contrast, lack of special symptoms such as jaundice or
pain in the earlier stages may lead to larger tumors in
peripheral ICC at diagnosis. In the present study, mean
tumor diameters in central and peripheral ICC were
6.7 ± 2.7 cm and 9.0 ± 3.4 cm (P = 0.003), respectively.
Because a higher control rate is typically obtained for
smaller tumors using the same radiation dose, response
to radiotherapy (CR+PR) for central ICC was better
than peripheral ICC (central ICC, 58.3%; peripheral ICC,
26.1%; P = 0.061).
Systemic chemotherapy for cholangiocarcinoma is
administered to patients who are not candidates for sur-
gery, gemcitabine or fluoropyrimidine are commonly
utilized for the treatment of advanced disease. Although
Figure 2 Overall survival curves for EBRT and non-EBRT groups.
Table 4 Survival time and response rate in central and
peripheral intrahepatic cholangiocarcinoma (ICC)
Central ICC Peripheral ICC P-value
Median survival time (months)
Non-EBRT group 3.5 ± 1.1 5.4 ± 0.7 0.103
EBRT group 13.3 ± 3.6 8.5 ± 0.9 0.205
CR+PR, n (%) 7 (58.3%) 6 (26.1%) 0.061
Diameter of tumor (cm) 6.7 ± 2.7 9.0 ± 3.4 0.003
Non-EBRT group 7.3 ± 2.5 9.2 ± 3.6 0.071
EBRT group 5.9 ± 2.9 8.7 ± 3.1 0.015
ICC, intrahepatic cholangiocarcinoma; EBRT, external beam radiotherapy; CR,
complete response; PR, partial response.
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than the best supportive care [19], randomized, prospec-
tive trial data were lacking in this disease, no standard
chemotherapy regimen has yet been established [20].
However, data regarding chemotherapy are disappoint-
ing, but new regimen or combination of targeted ther-
apy has been showed a promising result recently
[21-23]. Systemic chemotherapy can be used for meta-
static disease, and chemotherapy combined with EBRT
may have an important role in preventing distant metas-
tases and enhancing the radiation effects. Unfortunately,
since its disappointing efficacy before, chemotherapy
was not recommended after the diagnosis of ICC for
patients in this study. This is a limitation for our
retrospective analysis, and also the direction we will
study next.
TACE has become an acceptable palliative treatment for
patients with unresectable HCC. Compared with systemic
chemotherapy, TACE reduces systemic side effects by
increasing the local concentration of chemotherapeutic
agents to specifically target cancer cells without damaging
healthy liver tissue. However, cholangiocarcinoma is
generally considered a hypovascular tumor; therefore, the
efficacy of TACE for treating cholangiocarcinoma is ques-
tionable, because chemotherapeutic agents or embolic
materials may not be much more effectively delivered to
the tumor. In the present study, the median survival for
ICC patients receiving TACE was 10.0 months, compared
Table 5 Univariate and multivariate survival analysis
Variables n Survival Status Univariate Multivariate
1-Year
(n)
2-Year
(n)
Median survival (months) P RR P
Sex
Male 51 24.2 4.4 7.8 ± 1.6 1
Female 33 25.6 11.0 6.7 ± 0.5 0.862 1.054 0.845
Age
≤60 years old 41 33.1 5.5 7.8 ± 1.6 1
>60 years old 43 16.5 8.2 6.7 ± 0.8 0.844 1.451 0.153
Clinical symptoms
Asymptomatic 15 21.8 6.7 6.7 ± 0.5 1
Symptomatic 69 66.7 19 13.1 ± 1.1 0.001 3.923 < 0.001
Diameter (cm)
≤5 13 53.8 23.1 13.3 ± 2.8 1
5-10 39 15.0 3.0 6.8 ± 0.5 2.476 0.025
≥10 32 23.6 3.9 5.2 ± 0.4 0.013 3.165 0.011
Intrahepatic lesions
Solitary 63 26.6 7.1 6.8 ± 1.0 1
Multiple nodules 21 18.5 6.2 5.2 ± 0.7 0.604 1.794 0.050
Tumor types
Peripheral ICC 57 20.8 6.2 6.7 ± 1.0 1
Central ICC 27 31.9 8.0 6.8 ± 2.5 0.843 1.663 0.079
LN metastases
Asynchronous 13 69.2 15.4 14.2 ± 2.3 1
Synchronous 71 15.5 5.2 5.9 ± 0.7 0.002 1.794 0.025
CA19-9 (U/L)
≤37 13 36.9 18.5 7.8 ± 2.4 1
37-600 26 32.6 4.1 9.6 ± 1.4 1.639 0.232
≥600 45 16.4 5.5 5.5 ± 0.7 0.307 1.343 0.451
EBRT
Yes 35 38.5 9.6 9.5 ± 1.1 1
No 49 14.6 4.9 5.1 ± 0.3 0.003 2.962 < 0.001
TACE
Yes 28 39.9 4.0 10.0 ± 1.4 1
No 56 16.6 8.3 5.9 ± 0.7 0.201 0.893 0.689
RR, relative risk; ICC, intrahepatic cholangiocarcinoma; LN, lymph node; EBRT, external beam radiotherapy; TACE, transarterial chemoembolization.
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P = 0.201), multivariate survival analysis revealed that
TACE treatment was not an independent factor affecting
survival (P = 0.893). In EBRT group, Median survival
times for treatment with TACE and non-TACE were 13.3
± 1.5 months versus 7.8 ± 1.0 months, which might sug-
gest that EBRT combined with TACE could improve the
over all survival time of unresectable ICC, though there
was no significant difference between these two groups
(log-rank P = 0.268). Recently, some authors have reported
improved survival for selected patients with unresectable
hypervascular ICC treated with TACE [24,25]. Thus,
further study is needed to determine which types of ICC
are suitable for TACE therapy.
Radiation has historically played only a minor role in
the management of patients with unresectable liver can-
cer, primarily because of low tolerance of the whole
liver to irradiation. In addition to liver toxicities, normal
tissues adjacent to the liver, including the stomach, duo-
denum, and kidneys are at risk for radiation injury if
these organs can not be spared from the dose. The
design of radiation fields with CT scanning has per-
mitted the delivery of a higher radiation dose (50-60
Gy/25-30 fractions) to localized tumors. Data from
HCCs during the same period in our institute reveal an
overall response rate of 76% for confined intrahepatic
HCC [26] and 96.8% for LN metastases from HCC [27].
HCC is more sensitive to radiation than ICC. In the pre-
sent study, the main failure pattern is still local recur-
rence or intrahepatic metastases (68.8% versus 76.1%)
with additional EBRT or without, thus new EBRT
techniques or concurrence of chemotherapy are needed
in the future.
In our study, we used conventional fractionated RT
(1.8-2.0 Gy per fraction, five fractions a week), because
liver was considered a late responding normal organ
with a low ratio of a/b, which means hypofractionated
RT may increase the later toxicity, but in China, hypo-
fractionated RT has been quite often employed. In a
recently published study, Liang et al [28] reported 128
cases of primary liver cancer treated by hypofractionated
3DCRT (4-5 Gy per fraction, three fractions a week)
with a median total dose of 53.6 Gy. However, 15%
RILD occurred (19/128), which could be attributed to
large fraction size and high total RT dose. On the other
hand, the development of stereotactic body radiotherapy
(SBRT) has substantially improved the spatial distribu-
tion of the administered dose (tumor dose/healthy tissue
dose ratio > 1). They have also opened up the immedi-
ate possibility of using higher doses per fraction than in
conventional regimens, because there is less need to
protect late-responding tissues if the dose they absorb
can be reduced, some reports have showed safety and
efficacy for intra-hepatic tumors [29,30].
Several limitations exist in the present study. First, this
evaluation was carried out retrospectively, which implies
all the disadvantages associated with retrospective stu-
dies. Thus, a prospective randomized trial is needed to
confirm our results. Second, the appropriate rational
dose for ICC is still unknown. In the present study, we
used 50-60 Gy as the standard dose, but the actual dose
varied from 30 Gy to 60 Gy. Therefore, caution must be
used when interpreting our findings, and bias due to a
positive natural course present in an individual patient
has to be taken into consideration.
Conclusions
In conclusion, due to the lack of other effective thera-
pies, radiotherapy could be used to treat unresectable
ICC to relieve symptoms such as jaundice and improve
survival. Patients with central ICC appear to benefit
more from radiation compared with patients with per-
ipheral ICC.
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